Skip to main content
SpringerLink
Log in
Book cover

Histone Deacetylases: the Biology and Clinical Implication pp 103–123Cite as

Rationale for HDAC Inhibitor Therapy in Autoimmunity and Transplantation

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 206))

Abstract

While there are currently more than 70 ongoing clinical trials of inhibitors of so-called classical HDACs (HDACi) as anticancer therapies, given their potency as antiproliferative and angiostatic agents, HDACi also have considerable therapeutic potential as anti-inflammatory and immunosuppressive drugs. The utility of HDACi as anti-inflammatory agents is dependent upon their proving safe and effective in experimental models. Current pan-HDACi compounds are not well suited to this role, given the broad distribution of target HDACs and their complex and multifaceted mechanisms of action. In contrast, the development of isoform-selective HDACi may provide important new tools for therapy in autoimmunity and transplantation. This chapter discusses which HDACs are worthwhile targets in inflammation and progress toward their therapeutic inhibition, including the use of HDAC subclass and isoform-selective HDACi to promote the functions of Foxp3+ T regulatory cells.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Adcock IM (2007) HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150(7):829–831

    Article  PubMed  CAS  Google Scholar 

  • Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL, Hancock WW (2010) Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 136:348–363

    Article  PubMed  CAS  Google Scholar 

  • Alamdari N, Smith IJ, Aversa Z, Hasselgren PO (2010) Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 299(2):R509–R520

    Article  PubMed  CAS  Google Scholar 

  • Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11(9):854–861

    Article  PubMed  CAS  Google Scholar 

  • Ashburner BP, Westerheide SD, Baldwin AS Jr (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21(20):7065–7077

    Article  PubMed  CAS  Google Scholar 

  • Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A, Suzuki H, Hayashizaki Y, Hume DA, Sweet MJ, Ravasi T (2006) LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 20(9):1315–1327

    Article  PubMed  CAS  Google Scholar 

  • Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22(5):1026–1034

    Article  PubMed  CAS  Google Scholar 

  • Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280(29):26729–26734

    Article  PubMed  CAS  Google Scholar 

  • Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20–21

    Article  PubMed  CAS  Google Scholar 

  • Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10(3):197–204

    Article  PubMed  CAS  Google Scholar 

  • Boros P, Ochando JC, Chen SH, Bromberg JS (2010) Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol 71(11):1061–1066

    Article  PubMed  CAS  Google Scholar 

  • Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkuhler C, Gallinari P, Carfi A (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283(39):26694–26704

    Article  PubMed  CAS  Google Scholar 

  • Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6(3):238–243

    Article  PubMed  CAS  Google Scholar 

  • Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109(3):1123–1130

    Article  PubMed  CAS  Google Scholar 

  • Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27(1):68–73

    Article  PubMed  CAS  Google Scholar 

  • Bush EW, McKinsey TA (2010) Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 106(2):272–284

    Article  PubMed  CAS  Google Scholar 

  • Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132(31):10842–10846

    Article  PubMed  CAS  Google Scholar 

  • Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164(1–2):10–21

    Article  PubMed  CAS  Google Scholar 

  • Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J (2010) HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 56(3):437–444

    Article  PubMed  CAS  Google Scholar 

  • Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Dinarello CA, Rubartelli A (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 108(5):1618–1626

    Article  PubMed  CAS  Google Scholar 

  • Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, Yokochi T (2000) The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 6(3):243–247

    PubMed  CAS  Google Scholar 

  • Chen L, Fischle W, Verdin E, Greene WC (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293(5535):1653–1657

    Article  CAS  Google Scholar 

  • Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP (2008) A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 51(12):3437–3448

    Article  PubMed  CAS  Google Scholar 

  • Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY (2005a) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35(1):89–96

    Article  PubMed  CAS  Google Scholar 

  • Choi JH, Nam KH, Kim J, Baek MW, Park JE, Park HY, Kwon HJ, Kwon OS, Kim DY, Oh GT (2005b) Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25(11):2404–2409

    Article  PubMed  CAS  Google Scholar 

  • Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834–840

    Article  PubMed  CAS  Google Scholar 

  • Chung Y-L, Lee M-Y, Wang A-J, Yao L-F (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8(5):707–717

    Article  PubMed  CAS  Google Scholar 

  • de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138:583–594

    Article  PubMed  CAS  Google Scholar 

  • Edens RE, Dagtas S, Gilbert KM (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int Immunopharmacol 6(11):1673–1681

    Article  PubMed  CAS  Google Scholar 

  • Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45(7):737–744

    Article  PubMed  CAS  Google Scholar 

  • Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 36(2):269–279

    Article  PubMed  CAS  Google Scholar 

  • Finkelstein RA, Li Y, Liu B, Shuja F, Fukudome E, Velmahos GC, deMoya M, Alam HB (2010) Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock. J Surg Res 163(1):146–154

    Article  PubMed  CAS  Google Scholar 

  • Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9(1):45–57

    Article  PubMed  CAS  Google Scholar 

  • Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336

    Article  PubMed  CAS  Google Scholar 

  • Fukuchi M, Nii T, Ishimaru N, Minamino A, Hara D, Takasaki I, Tabuchi A, Tsuda M (2009) Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci Res 65(1):35–43

    Article  PubMed  CAS  Google Scholar 

  • Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846–853

    Article  PubMed  CAS  Google Scholar 

  • Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277(28):25748–25755

    Article  PubMed  CAS  Google Scholar 

  • Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176(8):5015–5022

    PubMed  CAS  Google Scholar 

  • Glauben R, Sonnenberg E, Zeitz M, Siegmund B (2009) HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 280(2):154–159

    Article  PubMed  CAS  Google Scholar 

  • Gloire G, Horion J, El Mjiyad N, Bex F, Chariot A, Dejardin E, Piette J (2007) Promoter-dependent effect of IKKalpha on NF-kappaB/p65 DNA binding. J Biol Chem 282(29):21308–21318

    Article  PubMed  CAS  Google Scholar 

  • Glozak MA, Seto E (2009) Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem 284(17):11446–11453

    Article  PubMed  CAS  Google Scholar 

  • Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, Prakken BJ, Maslinski W, Eldering E, Tak PP, Reedquist KA (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 184(5):2718–2728

    Article  PubMed  CAS  Google Scholar 

  • Gray SG, Dangond F (2006) Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1(2):67–75

    Article  PubMed  Google Scholar 

  • Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG (2010) Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116(6):935–944

    Article  PubMed  CAS  Google Scholar 

  • Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96(9):4868–4873

    Article  PubMed  CAS  Google Scholar 

  • Guillonneau C, Picarda E, Anegon I (2010) CD8+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant 15(6):751–756

    Article  Google Scholar 

  • Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100(8):4389–4394

    Article  PubMed  CAS  Google Scholar 

  • Halili MA, Andrews MR, Sweet MJ, Fairlie DP (2009) Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9(3):309–319

    Article  PubMed  CAS  Google Scholar 

  • Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP, Sweet MJ (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87(6):1103–1114

    Article  PubMed  CAS  Google Scholar 

  • Hamalainen M, Lilja R, Kankaanranta H, Moilanen E (2008) Inhibition of iNOS expression and NO production by anti-inflammatory steroids. Reversal by histone deacetylase inhibitors. Pulm Pharmacol Ther 21(2):331–339

    Article  PubMed  CAS  Google Scholar 

  • Han SB, Lee JK (2009) Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 32(4):613–624

    Article  PubMed  CAS  Google Scholar 

  • Han A, He J, Wu Y, Liu JO, Chen L (2005) Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 345(1):91–102

    Article  PubMed  CAS  Google Scholar 

  • Hancock WW, Wang L, de Zoeten EF, Bradner JE, Mazitschel R (2008) HDAC6 is a key new epigenetic target for the enhancement of Treg production and function in vitro and in vivo. Am J Transplant 8(Suppl 2):223

    Google Scholar 

  • Hoffmann K, Czapp M, Loscher W (2008) Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases? Epilepsy Res 81(2–3):107–113

    Article  PubMed  CAS  Google Scholar 

  • Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061

    Article  PubMed  CAS  Google Scholar 

  • Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de Los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307(2):720–728

    Article  PubMed  CAS  Google Scholar 

  • Huang L (2006) Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 209(3):611–616

    Article  PubMed  CAS  Google Scholar 

  • Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417(6887):455–458

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Barnes PJ, Adcock IM (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20(18):6891–6903

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM (2002a) Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 166(3):392–396

    Article  PubMed  Google Scholar 

  • Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ (2002b) A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99(13):8921–8926

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352(19):1967–1976

    Article  PubMed  CAS  Google Scholar 

  • Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, Fairlie DP, Brown L (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159(7):1408–1417

    Article  PubMed  CAS  Google Scholar 

  • Johnson J, Pahuja A, Graham M, Hering B, Hancock WW, Bansal-Pakala P (2008) Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+ regulatory T cells in rhesus macaques. Transplant Proc 40(2):459–461

    Article  PubMed  CAS  Google Scholar 

  • Jones P, Altamura S, De Francesco R, Paz OG, Kinzel O, Mesiti G, Monteagudo E, Pescatore G, Rowley M, Verdirame M, Steinkuhler C (2008a) A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem 51(8):2350–2353

    Article  PubMed  CAS  Google Scholar 

  • Jones P, Altamura S, De Francesco R, Gallinari P, Lahm A, Neddermann P, Rowley M, Serafini S, Steinkuhler C (2008b) Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 18(6):1814–1819

    Article  PubMed  CAS  Google Scholar 

  • Jung ID, Lee JS, Jeong YI, Lee CM, Chang JH, Jeong SK, Chun SH, Park WS, Han J, Shin YK, Park YM (2009) Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int J Immunopathol Pharmacol 22(2):501–515

    PubMed  CAS  Google Scholar 

  • Jung SB, Kim CS, Naqvi A, Yamamori T, Mattagajasingh I, Hoffman TA, Cole MP, Kumar A, Dericco JS, Jeon BH, Irani K (2010) Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res 107(7):877–887

    Article  PubMed  CAS  Google Scholar 

  • Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E, Koteish AA (2010) Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52(3):1033–1045

    Article  PubMed  CAS  Google Scholar 

  • Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M, Adcock IM, Moilanen E, Zhang X (2010) Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. J Inflamm (Lond) 7:9

    Article  CAS  Google Scholar 

  • Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4(4):337–342

    Article  PubMed  CAS  Google Scholar 

  • Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278(4):2758–2766

    Article  PubMed  CAS  Google Scholar 

  • Klampfer L, Huang J, Swaby LA, Augenlicht L (2004) Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279(29):30358–30368

    Article  PubMed  CAS  Google Scholar 

  • Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112(6):2340–2352

    Article  PubMed  CAS  Google Scholar 

  • Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18(5):601–607

    Article  PubMed  CAS  Google Scholar 

  • Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K (2000) Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 96(4):1490–1495

    PubMed  CAS  Google Scholar 

  • Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD (2008) Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 51(15):4370–4373

    Article  PubMed  CAS  Google Scholar 

  • Kramer OH, Heinzel T (2010) Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 315(1–2):40–48

    Article  PubMed  CAS  Google Scholar 

  • Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH, Stauber RH, Bohmer FD, Heinzel T (2009) A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 23(2):223–235

    Article  PubMed  CAS  Google Scholar 

  • Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM (2007) Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 17(10):2874–2878

    Article  PubMed  CAS  Google Scholar 

  • Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, Bottomley MJ, Lo Surdo P, Carfi A, Koch U, De Francesco R, Steinkuhler C, Gallinari P (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 104(44):17335–17340

    Article  PubMed  CAS  Google Scholar 

  • Lam AL, Pazin DE, Sullivan BA (2005) Control of gene expression and assembly of chromosomal subdomains by chromatin regulators with antagonistic functions. Chromosoma 114(4):242–251

    Article  PubMed  Google Scholar 

  • Lee AY, Paweletz CP, Pollock RM, Settlage RE, Cruz JC, Secrist JP, Miller TA, Stanton MG, Kral AM, Ozerova ND, Meng F, Yates NA, Richon V, Hendrickson RC (2008) Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J Proteome Res 7(12):5177–5186

    Article  PubMed  CAS  Google Scholar 

  • Lei J, Hasegawa H, Matsumoto T, Yasukawa M (2010) Peroxisome proliferator-activated receptor alpha and gamma agonists together with TGF-{beta} convert human CD4+CD25- T Cells into functional Foxp3+ regulatory T cells. J Immunol 185(12):7186–7198

    Article  PubMed  CAS  Google Scholar 

  • Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 34(6):776–787

    Article  PubMed  CAS  Google Scholar 

  • Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99(5):2995–3000

    Article  PubMed  CAS  Google Scholar 

  • Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11(1–12):1–15

    Article  PubMed  CAS  Google Scholar 

  • Li N, Zhao D, Kirschbaum M, Zhang C, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D (2008) HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 105(12):4796–4801

    Article  PubMed  CAS  Google Scholar 

  • Li Y, Liu B, Zhao H, Sailhamer EA, Fukudome EY, Zhang X, Kheirbek T, Finkelstein RA, Velmahos GC, deMoya M, Hales CA, Alam HB (2009) Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock 32(5):517–523

    Article  PubMed  CAS  Google Scholar 

  • Li Y, Liu B, Fukudome EY, Kochanek AR, Finkelstein RA, Chong W, Jin G, Lu J, deMoya MA, Velmahos GC, Alam HB (2010) Surviving lethal septic shock without fluid resuscitation in a rodent model. Surgery 148(2):246–254

    Article  PubMed  Google Scholar 

  • Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150(7):862–872

    Article  PubMed  CAS  Google Scholar 

  • Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP (2009) Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 257(1–2):97–104

    Article  PubMed  CAS  Google Scholar 

  • Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T (2010) Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 53(12):2569–2578

    Article  PubMed  CAS  Google Scholar 

  • Mai A (2007) The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 11(6):835–851

    Article  PubMed  CAS  Google Scholar 

  • Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48(9):3344–3353

    Article  PubMed  CAS  Google Scholar 

  • Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T (2010) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298(1):F133–F141

    Article  PubMed  CAS  Google Scholar 

  • Marwick JA, Kirkham PA, Stevenson CS, Danahay H, Giddings J, Butler K, Donaldson K, Macnee W, Rahman I (2004) Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 31(6):633–642

    Article  PubMed  CAS  Google Scholar 

  • Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G (2001) 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 44(13):2069–2072

    Article  PubMed  CAS  Google Scholar 

  • Miao F, Gonzalo IG, Lanting L, Natarajan R (2004) In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 279(17):18091–18097

    Article  PubMed  CAS  Google Scholar 

  • Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111(4):539–552

    PubMed  CAS  Google Scholar 

  • Moodie FM, Marwick JA, Anderson CS, Szulakowski P, Biswas SK, Bauter MR, Kilty I, Rahman I (2004) Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 18(15):1897–1899

    PubMed  CAS  Google Scholar 

  • Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, Choi GS, Kwan JH, Joh JW, Kim SJ (2009) Use of epigenetic modification to induce FOXP3 expression in naive T cells. Transplant Proc 41(5):1848–1854

    Article  PubMed  CAS  Google Scholar 

  • Moreira JM, Scheipers P, Sorensen P (2003) The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3(1):30

    Article  PubMed  Google Scholar 

  • Muraglia E, Altamura S, Branca D, Cecchetti O, Ferrigno F, Orsale MV, Palumbi MC, Rowley M, Scarpelli R, Steinkuhler C, Jones P (2008) 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med Chem Lett 18(23):6083–6087

    Article  PubMed  CAS  Google Scholar 

  • Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 184(6):3106–3116

    Article  PubMed  CAS  Google Scholar 

  • Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 175(9):5809–5816

    PubMed  CAS  Google Scholar 

  • Nebbioso A, Manzo F, Miceli M, Conte M, Manente L, Baldi A, De Luca A, Rotili D, Valente S, Mai A, Usiello A, Gronemeyer H, Altucci L (2009) Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 10(7):776–782

    Article  PubMed  CAS  Google Scholar 

  • Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 50(10):3365–3376

    Article  PubMed  CAS  Google Scholar 

  • Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB (2009) Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 297(3):F729–F739

    Article  PubMed  CAS  Google Scholar 

  • Nusinzon I, Horvath CM (2003) Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 100(25):14742–14747

    Article  PubMed  CAS  Google Scholar 

  • Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T (2010) A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. doi:10.1007/s10637-010-9493-4

  • Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW (2009) Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J 30(3):266–277

    Article  PubMed  CAS  Google Scholar 

  • Porter JR, Fritz CC, Depew KM (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14(3):412–420

    Article  PubMed  CAS  Google Scholar 

  • Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O (2003) Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101(9):3451–3459

    Article  PubMed  CAS  Google Scholar 

  • Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101(11):3921–3926

    Article  PubMed  CAS  Google Scholar 

  • Reilly CM, Thomas M, Gogal R Jr, Olgun S, Santo A, Sodhi R, Samy ET, Peng SL, Gilkeson GS, Mishra N (2008) The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 31(2):123–130

    Article  PubMed  CAS  Google Scholar 

  • Richon VM, O'Brien JP (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8(3):662–664

    PubMed  Google Scholar 

  • Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97(18):10014–10019

    Article  PubMed  CAS  Google Scholar 

  • Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stockl J, Horl WH, Zlabinger GJ (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 14(15):2380–2382

    PubMed  CAS  Google Scholar 

  • Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW, Greene MI (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 87(2):99–104

    Article  PubMed  CAS  Google Scholar 

  • Schafer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, Strasser A, Dickmanns A, Ficner R, Schlimme S, Sippl W, Verdin E (2008) Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem 16(4):2011–2033

    Article  PubMed  CAS  Google Scholar 

  • Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH (2008) Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283(17):11355–11363

    Article  PubMed  CAS  Google Scholar 

  • Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA (2008) Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 283(30):21065–21073

    Article  PubMed  CAS  Google Scholar 

  • Smil DV, Manku S, Chantigny YA, Leit S, Wahhab A, Yan TP, Fournel M, Maroun C, Li Z, Lemieux AM, Nicolescu A, Rahil J, Lefebvre S, Panetta A, Besterman JM, Deziel R (2009) Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett 19(3):688–692

    Article  PubMed  CAS  Google Scholar 

  • Suen JY, Gardiner B, Grimmond S, Fairlie DP (2010) Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS ONE 5(11):e13809

    Article  PubMed  CAS  Google Scholar 

  • Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A (2003) Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 87(2):407–416

    Article  PubMed  CAS  Google Scholar 

  • Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J Med Chem 49(16):4809–4812

    Article  PubMed  CAS  Google Scholar 

  • Tao R, Hancock WW (2008) Resistance of Foxp3+ regulatory T cells to Nur77-induced apoptosis promotes allograft survival. PLoS ONE 3(5):e2321

    Article  PubMed  CAS  Google Scholar 

  • Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13(11):1299–1307

    Article  PubMed  CAS  Google Scholar 

  • Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272(5260):408–411

    Article  PubMed  CAS  Google Scholar 

  • Toropainen S, Vaisanen S, Heikkinen S, Carlberg C (2010) The down-regulation of the human MYC gene by the nuclear hormone 1alpha,25-dihydroxyvitamin D3 is associated with cycling of corepressors and histone deacetylases. J Mol Biol 400(3):284–294

    Article  PubMed  CAS  Google Scholar 

  • Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18(6):291–297

    Article  PubMed  CAS  Google Scholar 

  • Van Kaer L (2010) Comeback kids: CD8(+) suppressor T cells are back in the game. J Clin Invest 120(10):3432–3434

    Article  PubMed  CAS  Google Scholar 

  • Van Lint C, Emiliani S, Verdin E (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5(4–5):245–253

    PubMed  Google Scholar 

  • Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10(1):92–100

    Article  PubMed  CAS  Google Scholar 

  • Villagra A, Sotomayor EM, Seto E (2010) Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29(2):157–173

    Article  PubMed  CAS  Google Scholar 

  • Vlad G, King J, Chang CC, Liu Z, Friedman RA, Torkamani AA, Suciu-Foca N (2010) Gene profile analysis of CD8(+) ILT3-Fc induced T suppressor cells. Hum Immunol 72(2):107–114

    Article  PubMed  CAS  Google Scholar 

  • Wang L, de Zoeten EF, Greene MI, Hancock WW (2009a) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 8(12):969–981

    PubMed  CAS  Google Scholar 

  • Wang L, Tao R, Hancock WW (2009b) Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 87(3):195–202

    Article  PubMed  CAS  Google Scholar 

  • Wang L, Katsumata M, Li B, Kasler H, Han R, Greene MI, Verdin EM, Hancock WW (2009c) HDAC7 targeting enhances Foxp3+ Treg function and induces long-term allograft survival. Am J Transplant 9(Suppl 2):621

    Google Scholar 

  • Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS (2009) A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell 136(6):1056–1072

    Article  PubMed  CAS  Google Scholar 

  • Wong PG, Glozak MA, Cao TV, Vaziri C, Seto E, Alexandrow MG (2010) Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell Cycle 9(21):4351–4363

    Article  PubMed  CAS  Google Scholar 

  • Xu M, Nie L, Kim SH, Sun XH (2003) STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J 22(4):893–904

    Article  PubMed  CAS  Google Scholar 

  • Yin L, Laevsky G, Giardina C (2001) Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276(48):44641–44646

    Article  PubMed  CAS  Google Scholar 

  • Yuan Z, Peng L, Radhakrishnan R, Seto E (2010) Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. J Biol Chem 285(50):39329–39338

    Article  PubMed  CAS  Google Scholar 

  • Zhang CL, McKinsey TA, Lu JR, Olson EN (2001) Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J Biol Chem 276(1):35–39

    Article  PubMed  CAS  Google Scholar 

  • Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110(4):479–488

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28(5):1688–1701

    Article  PubMed  CAS  Google Scholar 

  • Zhang ZY, Zhang Z, Schluesener HJ (2010a) MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169(1):370–377

    Article  PubMed  CAS  Google Scholar 

  • Zhang L, Jin S, Wang C, Jiang R, Wan J (2010b) Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis. World J Surg 34(7):1676–1683

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplant Immunology, Department of Pathology and Laboratory Medicine, 916B Abramson Research Center, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, 3615 Civic Center Boulevard, Philadelphia, PA, 19104-4318, USA

    Wayne W. Hancock

Authors
  1. Wayne W. Hancock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne W. Hancock .

Editor information

Editors and Affiliations

  1. , Department of Pharmacology, Duke University, Durham, 27710, North Carolina, USA

    Tso-Pang Yao

  2. , Department of Molecular Oncology, H.Lee Moffitt Cancer Center & Research I, Magnolia Drive 12902, Tampa, 33612, Florida, USA

    Edward Seto

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hancock, W.W. (2011). Rationale for HDAC Inhibitor Therapy in Autoimmunity and Transplantation. In: Yao, TP., Seto, E. (eds) Histone Deacetylases: the Biology and Clinical Implication. Handbook of Experimental Pharmacology, vol 206. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21631-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation